This is a routine industry networking event with no immediate stock-moving catalyst. Monitor for any subsequent regulatory or clinical updates from the Phase IIa trials, which are the primary value drivers for this clinical-stage biotech.
Price Chart
Executive Summary
Clearmind Medicine's CEO participated in an invite-only federal policy summit at the National Press Club, convened by the Psychedelic Medicine Coalition, alongside U.S. lawmakers and federal officials. The event is a non-financial, routine industry advocacy milestone with no material impact on the company's financials or clinical pipeline.
Key Facts
- CEO Dr. Adi Zuloff-Shani was a delegate at the Psychedelic Medicine Coalition's Federal Policy Summit on May 14, 2026, at the National Press Club in Washington, D.C.
- The summit included U.S. Senators, Representatives, HHS Deputy General Counsel, NIH's NIDA Director, and researchers from Johns Hopkins, Harvard, and Yale.
- Clearmind is advancing a non-hallucinogenic psychedelic candidate with Phase IIa trials underway at Johns Hopkins, Yale, and other sites.
- No financial figures, deal values, guidance, or clinical data were disclosed in the press release.
Financial Impact
No financial impact disclosed; event is a policy advocacy meeting with no direct revenue or cost implications.
Risk Factors
- No material financial or operational changes from this event; stock remains driven by clinical trial outcomes and capital position.
- Phase IIa trial results are pending and carry inherent clinical risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295847 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $6.12 (−2.02%) |
Oct 13, 2026 14d ago | 6-K | $6.23 | awaiting T+60 | — | $6.12 (−1.75%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.12 (−10.82%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.12 (+548.41%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $6.12 (+494.27%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $6.12 (−427.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers